Pfizer has decided to join the in vivo CAR-T race, penning a $2.6 billion deal for three preclinical candidates from China’s Starna Therapeutics.
In return for a $330 million upfront fee, Pfizer has secured the ex-China rights to three in vivo CAR-T programs that are focused on treating autoimmune diseases. The programs are currently in “pre-IND” development, the pharma explained in a Nov. 18 release.
Under the deal, which is tied to up to $2.3 billion in milestone payments plus royalties, Pfizer will take the lead on the programs’ clinical development outside Greater China—although the pharma has the option to also bag the China rights at a later date.
The current plan is to manufacture the finished drug product for those early trials using Pfizer’s U.S. sites, according to the company.
The deal combines two hot areas of Big Pharma deal-making: in vivo therapies and turning CAR-Ts toward autoimmune indications. Eli Lilly has acquired two in vivo CAR-T biotechs this year in the form of Kelonia Therapeutics and Orna Therapeutics, with the latter deal focused on autoimmune conditions. Meanwhile, Kyverna Therapeutics is currently awaiting an FDA decision on whether to grant the first-ever approval for an autoimmune CAR-T therapy.
While Pfizer already has in vivo expertise when it comes to gene editing therapy development via its collaboration with Beam Therapeutics, today’s deal with Starna marks the pharma’s first dip into in vivo CAR-Ts specifically.
“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short,” Pfizer’s Chief Inflammation and Immunology Officer Michael Vincent, M.D., Ph.D., explained in the release.
“Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches,” Vincent added.
The deal even spans beyond autoimmune CAR-Ts, with Pfizer securing the rights to use the programs for oncology, as well as a chance to license compounds from a separate collaboration —although the companies didn’t go into more detail.
Jiangsu-based Starna was founded in 2021 and has been developing a pipeline of mRNA therapies that includes in vivo cell therapies, therapeutic cancer vaccines and a vaccine for respiratory syncytial virus infection. The biotech’s $44 million series B in May was backed by the likes of Lilly Asia Ventures and Primavera Capital.
“Our vision at Starna is to unlock the potential of RNA medicines to transform patient care,” Starna CEO Rongkuan Hu, Ph.D., said in the release.
“We believe our proprietary targeted LNP delivery platform and RNA technology provide a strong foundation for advancing in vivo CAR-T therapies,” Hu added. “We are excited to join forces with Pfizer, a global leader in drug development, to bring transformative therapies to patients worldwide.”